LEL Lilly(Eli)

 
TIDMLEL 
 
Date: July 29, 2011 
 
For Release: Immediately 
 
Refer to: (317) 276-5795 - Mark Taylor 
 
      U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent 
 
          AppealsCourt Decision Overturns Prior District Court Ruling 
 
Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Court of Appeals 
for the Federal Circuit has overturned a prior ruling by the U.S. District 
Court for the District of New Jersey and has upheld the validity of the 
company's method-of-use patent on Strattera® (atomoxetine). In the case of Eli 
Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled in favor of 
Lilly, upholding the method-of-use patent which provides protection for 
Strattera through May of 2017. 
 
"We are pleased with today's ruling from the Court of Appeals regarding 
Strattera's method-of-use patent and remain confident that the patent is valid 
and enforceable," said Robert A. Armitage, senior vice president and general 
counsel for Lilly. "In overturning the prior district court ruling, we believe 
that the Court fairly applied long-standing patent law principles." 
 
Lilly, a leading innovation-driven corporation, is developing a growing 
portfolio of pharmaceutical products by applying the latest research from its 
own worldwide laboratories and from collaborations with eminent scientific 
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - 
through medicines and information - for some of the world's most urgent medical 
needs. Additional information about Lilly is available at www.lilly.com. C-LLY 
 
This release contains forward-looking statements regarding the U.S. Strattera 
patent litigation. These statements are based on management's current 
expectations but actual results may differ materially. There can be no 
assurance that the company will prevail in any appeal. Other risk factors that 
may affect the company's results can be found in the company's latest Forms 
10-K and 10-Q filed with the U.S. Securities and Exchange Commission. 
 
                                     # # # 
 
Strattera® (atomoxetine, Lilly) 
 
 
 
Eli Lilly and Company 
 
Lilly Corporate Center 
 
Indianapolis, Indiana 46285 
 
U.S.A. 
 
www.lilly.com 
 
 
 
 
 
 
 
                                     - 2 - 
 
 
 
 
END 
 

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025